Impact ledger
Disc Medicine, Inc. (DISC): the developments shaping its investment case
Follow the evidence affecting Disc Medicine, Inc.. Review the key developments below. Continue in Market Ontology to test your assumptions, examine related opportunities, and save the investment case you want to track.
Research Disc Medicine, Inc. · $399/mo
Test assumptions, examine opportunities, and save your research.
Material developments
2026-09-01 · 2 reports
Disc Medicine to Present Phase 2 Hematology Data at SOHO 2026
Channel: Direct clinical trial data release for lead assets, impacting future revenue potential and perceived risk.
mixed· 1-3m
Event impact log
2 events mapped to DISC since 2026-09-01. Evidence through 2026-09-01.
| Date | Event | Channel | Direction | Horizon | Impact |
|---|---|---|---|---|---|
| 2026-09-01 | Disc Medicine to Present Phase 2 Hematology Data at SOHO 2026 | Direct clinical trial data release for lead assets, impacting future revenue potential and perceived risk. | mixed | 1-3m | 0.90 |
| 2026-09-01 | Disc Medicine to Present Phase 2 RESTORE-PV and RALLY-MF Trial Data at SOHO | Direct clinical trial data readout for lead pipeline assets, impacting perceived efficacy and safety, and thus commercial potential. | mixed | 1-3m | 0.90 |
Continue this research
Build your Disc Medicine, Inc. investment case. Continue from the evidence above, change the assumptions the developments move, and save the work to revisit as the case develops.
This ledger is regenerated from Market Ontology's public event pipeline. View the DISC entity page →